google-site-verification: googlec7193c3de77668c9.html
Saturday , September 5 2026

Targeted alpha therapy using astatine shows promise in thyroid cancer resistant to conventional treatment

[
A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, investigators found that a single dose of the alpha-emitting radionuclide 211At (astatine) was both well-tolerated and effective, achieving disease control without molecularly targeted drugs. The findings were published in the December issue of The Journal of Nuclear Medicine.


Source link

Advertisements

See also  How Anthropic trained its AI models on millions of books

Check Also

People affected by cancer need a stronger voice in shaping generative AI for oncology, review finds

[ Credit: Unsplash/CC0 Public Domain Flinders University researchers were part of an international team that …

Children’s suicide-related emergency visits spiked by 74% in the US between 2016–2022

[ Credit: Unsplash/CC0 Public Domain Emergency visits by children with suicide-related crises increased by 74% …

National call to action needed to strengthen primary care pipeline in medical education, argue experts

[ A new paper led by a faculty member at the Hackensack Meridian School of …

Leave a Reply

Available for Amazon Prime